Register for streaming realtime charts, analysis tools, and prices.
Period:
Draw Mode:
| Volume | 13,415 |
|
|||||
| News | - | ||||||
| Day High | 1.70 | Low High |
|||||
| Day Low | 1.4699 | ||||||
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Aptorum Group Ltd | APM | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded
|
|
|---|---|---|---|---|
| -0.01 | -0.59% | 1.68 | 20:00:00 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 1.59 | 1.4699 | 1.70 | 1.68 | 1.69 |
| Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
|---|---|---|---|---|---|
| 109 | 13,415 | $ 1.61 | $ 21,648 | - | 1.36 - 9.00 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 16:00:00 | 100 | $ 1.68 | USD |
Aptorum Group Ltd Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 7.01M | 4.17M | - | 1.3M | -9.8M | -2.35 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
Aptorum News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical APM Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 1.50 | 1.95 | 1.37 | 1.63 | 3,720 | 0.18 | 12.0% |
| 1 Month | 1.55 | 1.95 | 1.36 | 1.58 | 2,603 | 0.13 | 8.39% |
| 3 Months | 2.24 | 2.95 | 1.36 | 2.29 | 7,923 | -0.56 | -25.0% |
| 6 Months | 3.09 | 3.35 | 1.36 | 2.23 | 81,171 | -1.41 | -45.63% |
| 1 Year | 5.51 | 9.00 | 1.36 | 4.19 | 127,719 | -3.83 | -69.51% |
| 3 Years | 27.20 | 49.40 | 1.36 | 21.04 | 447,696 | -25.52 | -93.82% |
| 5 Years | 158.00 | 332.80 | 1.36 | 25.86 | 367,981 | -156.32 | -98.94% |
Aptorum Description
| Aptorum Group Ltd clinical-stage biopharmaceutical company. It is engaged in the discovery, development, and commercialization of therapeutic assets to treat diseases with unmet medical needs, particularly in oncology (including orphan oncology indications) and infectious diseases. The company operates in two segments: Therapeutics and Non-Therapeutics. Its lead projects are ALS-4, SACT-1, and RPIDD. It is also engaged in providing healthcare services. |
